ResMed Inc. with ticker code (RMD) have now 10 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 275 and 207 with the average target price sitting at $250.45. Given that the stocks previous close was at $179.47 this indicates there is a potential upside of 39.5%. The 50 day moving average now sits at $212.84 and the 200 day MA is $218.32. The company has a market capitalization of 26.57B. The stock price for the company is currently 180.85 USD
The potential market cap would be $37,081,830,977 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 30.91, revenue per share of 28.77 and a 12.15% return on assets.
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
